Immune Defense Protein Impact On Respiratory Immune Outcomes
Trial Parameters
Brief Summary
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
Eligibility Criteria
Inclusion Criteria: 1. Age 60 years and older 2. Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season. 3. Able to read and understand English. 4. Able to read, understand, and provide informed consent. 5. Able to use a personal smartphone device and download Chloe by People Science. 6. Able to receive shipment of the product at an address within the United States. Exclusion Criteria: Any potential participants who: 1. Do not have a personal smartphone, internet access, or unwilling to download Chloe. 2. Already in an immunocompromised state, including: A. Infectious Causes * HIV/AIDS * Chronic hepatitis B or C (advanced stages) * Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related * Leukemia (e.g., AML, ALL, CLL) * Lymphoma (e.g., Hodgkin's and Non-Hodgkin's) * Multiple Myeloma * Any metastatic cancer receiving chemotherapy C. Immunosuppressive Therapy: Participants on: * Cort